Lutronic has thus extended the already wide scope of the SPECTRA family, so that the SPECTRA XT takes over and advances from the very high goals already reached by the proven SPECTRA family. In addition to the more efficient removal of tattoos, SPECTRA XT has added New Generation 595 nm Gold Toning as a novel and effective approach to recalcitrant post-acne redness, post-laser erythema and melasma with an underlying dermal vascular component, and 660 nm RuVY Touch as a safer treatment for discrete epidermal pigmented lesions (freckles, lentigines) on and off the face, e.g., the neck, décolleté and dorsal aspect of the upper extremities. The 300 μs quasi long-pulsed mode delivering up to 45 J over 1 second offers flexible and tailored treatment for onychomycosis, and therefore even delivery of heat to the nail, nail bed and surrounding skin. The large 10 mm spot has proved ideal for low-fluence Q-switched 1064 nm laser toning with faster treatment times, and can be combined in Q-switched mode with the Q-PTP and Optimum Lattice Technologies for gentler and more efficient treatments. SPECTRA XT – the extended platform – offers the clinician and his or her patients extended functionality and efficacy with extended reliability and flexibility.
Café au lait macule (CALM) is a benign epidermal hyperpigmentation disorder that can be idiopathic or associated with neurocutaneous syndromes. CALM responds to many therapeutic methods showing various treatment outcomes and recurrence rates. Each laser of 755 nm alexandrite and 1,064 nm Nd:YAG toning is used for treatment of benign pigmented lesions, however there is no combination approach for use of these lasers for treatment of CALM. This report describes the case of a 20-year-old male who presented with CALM on his face without a personal or family medical history associated with neurofibromatosis. In this case, combination laser of 755 nm alexandrite laser with 1,064 nm Nd-YAG laser toning showed relatively high efficacy in removing CALM without re-pigmentation.
Seven patients completed the study. No significant differences were found in the PSI, GAIS, patient satisfaction score, and melanin average score between the lasers. The melanin average level was significantly reduced by the 660- m laser but not the 532-nm laser at Week 8 compared with the baseline. Both 660-nm and 532-nm QS Nd:YAG lasers effectively reduce pigmentation for up to 8 weeks with high patient satisfaction. The new 660-nm laser therefore increases the treatment options for lentigines in Asian skin.
Erythematotelangiectatic rosacea presents as persistent erythema and telangiectasia with frequent flushing and blushing on the facial and extrafacial skin. Additionally, papulopustular rosacea shows acneiform papules, pustules, and nodules with persistent plaque-form edema. Despite garnering only grade-C or -D level recommendations, a 585-nm or 595-nm flashlamp-pumped pulsed-dye laser can be considered as an effective therapeutic modality for the treatment of rosacea in patients who are refractory to topical and/or systemic treatments. In this report, treatment with a Q-switched 595-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser with low non-purpuragenic fluence proved to be safe and effective in treating early-stage erythematotelangiectatic rosacea in two female Korean patients. Laser treatment for rosacea was delivered with the settings of pulse energy of 0.4–0.5 J/cm2, pulse duration of 5–10 ns, 5-mm spot size, 5 Hz, and 500 shots. Additionally, we found that remarkable therapeutic effects were achieved for both rosacea and melasma by combining Q-switched quick pulse-to-pulse 1,064-nm Nd:YAG and Q-switched 595-nm Nd:YAG laser treatments, which required only the changing of handpieces equipped with solid dye. In conclusion, we suggest that treatment with a Q-switched 595-nm Nd:YAG laser with low fluence may provide an additional therapeutic option for treating early-stage erythematotelangiectatic rosacea.
SPECTRA XT extends the capability of the clinician with its two new wavelengths, 595nm and 660nm, to deal more safely and effectively with a variety of inflammatory and pigmented targets. The 300µs quasi long-pulsed mode deliverable at 45J over 1 second offers flexible and tailored treatment for onychomycosis, and therefore gives even delivery of heat to the nail, nail bed and surrounding skin. The large 10mm spot has proved ideal for lowfluence 1064nm laser toning with faster treatment times, and can be combined with the Q-PTP and OLT for gentler and more efficient treatments, including tattoo removal. SPECTRA XT—the extended platform—extends the ability and scope of the clinician to treat his or her patients safely and effectively
Among the 20 subjects included in this study, the mean number of RuVY treatments performed was 1.3 ± 0.5, the mean global aesthetic improvement scale (GAIS) score was 2.1 ± 1.1, and the patients’ mean degree of satisfaction was 2.0 ± 1.0. Sixteen (80%) patients also received QS low-fluenced 1,064-nm Nd:YAG laser treatment while undergoing RuVY treatment, with or without a long-pulsed 755-nm alexandrite laser. They were treated with a mean of 6.9 ± 2.5 sessions of QS low-fluenced 1,064-nm Nd:YAG laser treatment for a mean GAIS score of 1.9 ± 1.1. Eight patients were treated with long-pulsed 755-nm alexandrite laser F51treatment over a mean number of 1.1 ± 0.4 sessions, showing a mean GAIS score of 1.8 ± 1.5. Our data suggest that RuVY treatment utilizing wavelength-converted 660-nm laser energy is effective in treatment of various epidermal pigmentation lesions.
Long-pulsed 755-nm alexandrite laser has been used effectively and safely for treatment of various pigmented lesions. However, in Asian patients, the risk of postinflammatory hyperpigmentation (PIH) is high when epidermal pigmented lesions are treated with this laser using a large beam size. In this report, we described a female patient with long-pulsed alexandrite laser treatment-induced PIH. We found that long-pulsed alexandrite laser-induced PIH presented clinically along with demarcated and darkly pigmented macules compared to PIH by other Q-switched pigment lasers. In addition, all of the lesions with PIH showed abrupt improvement rather than gradual improvement after eight sessions of 1,064-nm Q-switched Nd:YAG laser with low fluence. Additionally, we delivered 1,064-nm Nd:YAG laser energy on the PIH lesions using a quick pulse-to-pulse (Q-PTP) mode. We suggest that the additional use of a Q-PTP mode could have played an important role in the marked improvement of alexandrite-induced PIH.
Facial skin texture and tone on both sides of the face were noticeably improved after two sessions of Revital Treatment and Laser Genesis using each of the respective 1,064 nm 300 μs quasi long-pulsed Nd:YAG laser devices. One month after the final treatment, many of the keratin plugs in the patient’ facial pores were removed and symptoms of seborrhea had improved on both sides of the face. The patient reported being satisfied with the therapeutic effects of both laser treatments. No remarkable major side effects, including transient or persistent post-treatment erythema, were recorded on either side of the face. By safely delivering quasi F64long-pulsed high laser energy to target tissues, we suggest that Revital Treatment can be effectively used for the treatment of enlarged pores.
Melasma is a common disorder that clinically presents as symmetric illdefined hyperpigmented macules and patches on the face. In the current split-face, evaluator-blinded study, we treated a female patient with eight sessions of 1,064-nm Nd:YAG laser treatment at one-week intervals. Utilizing the Q-switched (QS) quick pulse-to-pulse (Q-PTP) mode, in reference to the laser settings, 1,064-nm Nd:YAG laser energy can be irradiated at split fluences and at a dual-pulse interval of 80-μsec. On the right side of the face, 1,064-nm QS single pulse Nd:YAG laser treatment was administered with the settings of 1.6 J/cm2, a spot size of 7-mm, and 1200 shots. On the left side, 1,064-nm QS Q-PTP Nd:YAG laser treatment was administered with the settings of 1.6 J/cm2 irradiated at dual pulses of 0.8 J/cm2 at 80-μsec intervals, a spot size of 7-mm, and 1,200 shots. Results of objective clinical assessment showed better clinical outcomes with less treatment-associated pain with QS Q-PTP- reatment than with QS single-pulse-treatment. However, clinical outcomes were subjectively indistinguishable between QS single pulse- and QS Q-PTP-treatments. Transient or persiste+F51nt post-treatment erythema and newly developed punctate leukoderma lesions were not reported for either side of the face. Pre-existing punctate leukoderma lesions became obscure, especially on the QS Q-PTP-treated side, with improvement of the melasma lesions. We suggest that the QS Q-PTP mode may be of use in treatment of melasma, particularly on the relatively thin skin of the periorbital regio+F54ns and in pain-sensitive and erythema-prone patients.